Endocrine Abstracts

Skin diseases in patients with type 2 diabetes mellitus (T2DM) are increased. Patients with T2DM and psoriasis have an increased risk of psoriasis exacerbations.

Objective:

to study the influence of T2DM on the psoriasis treatment.

Materials and methods

We studied hospitalized patients with T2D and psoriasis in dermatological clinic during 5 years (n = 47) - the main group. Comparison group 1- patients with psoriasis without T2D (n = 40), comparison group 2 - patients with T2D without psoriasis (n = 37). Patients were excluded: with the psoriatic arthritis, GFR ≤ 45 ml/min/1.73 m².

Results

Patients of the main group (women-53.2%, men-46.8%, mean age 61.0 ± 7.7 years), comparison group 1 (women-55%, men- 45%, mean age 60.5 ± 7.5 years), comparison group 2 (women-54%, men-46%, mean age 62.0 ± 7.8 years) were same in clinical, anthropometric, anamnestic and laboratory data (AST, ALT, total cholesterol, creatinine, p > 0.05). Patients of the main group and comparison group 1 differed in serum glycaemia (P = 0.005), HbA1c (P = 0.009). Patients of the main group had an increase HbA1c (11.8 (7.9–12.3)) compared with the comparison group 2 (6.8(6.1–7.3), P = 0.006) in the exacerbation of psoriasis period.

Duration of inpatient treatment of psoriasis until remission in patients of the main group was significantly longer (16.1 ± 2.4 days) compared with the comparison group 1 (13.0 ± 2.1 days, P = 0.041). The number of patients who needed the use of systemic glucocorticosteroid was higher in patients of the main group (14.9 %) compared with the comparison group 1 (2.5 %), F=0.05, P = 0.048.

Conclusions

There is probably a correlation between psoriasis exacerbation and T2DM decompensation. T2DM in patients with psoriasis can lead to a more severe exacerbation of psoriasis, which increases the duration of treatment and the frequency of systemic glucocorticosteroid use, which can lead to a decrease in DM2 control.